Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Mol Cancer Ther. 2023 Nov 1;22(11):1248–1260. doi: 10.1158/1535-7163.MCT-23-0031

Figure 1.

Figure 1.

Identification of CIDD-0149897 as novel ERβ agonist. A, Schematic representation of ERβ ligand design strategy and the structure of CIDD-0149897. B HEK293T model cells stably expressing ERβ or ERα along with ERE-Luc reporter was used for initial screening of compounds testing for ER activity (n=3). Heat map showing ERβ and ERα reporter activity of selective compounds (n=3). C, HEK293Tcells expressing ERβ or ERα were treated with various doses of CIDD-0149897 and ERE-Luc reporter activity was measured after 24 hours (n=2). D, U251 GBM cells expressing ERβ were treated with indicated doses of CIDD-0149897 or LY500307 and after 24 h, ERE-Luc reporter activity was measured (n=3). E. Effect of increasing doses of selected ERβ agonists on the cell viability of U251 GBM model cells expressing ERβ was measured using the MTT cell viability assay (n=3). F, Effect of increasing doses of CIDD-0149897 on the cell viability of indicated patients derived GSCs was measured using CellTiter Glo assay (n=3). Data are presented as mean ± SEM.